fashion -WSS

fashion

author：leisure time 2025-10-03 00:38:31 - browse：6123

Colorful broken DNA helix genome. -- health coverage from STAT — Adobe

In 2020, as biotech stocks surged amid the pandemic, a startup called Taysha Gene Therapies raised over $300 million off an audacious promise: It was going to license and develop gene therapies for at least 18 different rare and serious neurological diseases.

The effort brought hope for many rare disease families, some of whom had raised money to fund the UT-Southwestern scientist who designed the treatments after they saw no other options for their children.

Last week, the grand plan took perhaps a final blow. Taysha announced it would discontinue development of a treatment for giant axonal neuropathy, or GAN, a fatal, degenerative disease known to affect fewer than 100 people worldwide. The FDA, Taysha said, had requested an additional clinical trial that would be infeasible.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Citing H5N1 threat, CDC urges peak flu monitoring this summer

WSS

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

Hospitals owned by private equity see complications spike 25%

Eyeing GLP

Bird flu surveillance in wastewater gets boost from consortium

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

Listen: A conversation with researcher Kevin Esvelt on biosecurity

explore

fashion

hotspot

BioMarin wins approval for gene therapy to treat hemophilia A

Digital health: a case of mistaken identity

Medicare proposal to cover medical devices draws a mixed reaction

Bristol Myers buys into radiopharmaceuticals with RayzeBio

BioMarin wins approval for gene therapy to treat hemophilia A

Eyeing GLP

How one medical school became remarkably diverse

Violet CEO on training clinicians to promote more inclusive care

Medicare proposal to cover medical devices draws a mixed reaction

HCA sued by state AG for quality issues at Mission Health

leisure time

Citing H5N1 threat, CDC urges peak flu monitoring this summer

Liver decline slowed by off

Readout Newsletter: H5N1 bird flu vaccine, Cytokinetics, Gilead

Fentanyl is making it harder to start addiction treatment

As a primary care physician, here's how I hope to partner with AI

Readout Newsletter: The latest on Moderna, Apellis, and Merck

leisure time

explore

hotspot

leisure time